Safety-net hospitals (SNH) play a critical role in the US health-care system by serving the most vulnerable patients and improving access to care. The National Academy of Medicine and Centers for Medicare and Medicaid Services (CMS) define these hospitals by the relative volume of uninsured or Medicaid patients ([@pkz039-B1]). However, for incompletely understood reasons, likely a combination of patient risk factors, low resources, and management challenges, these hospitals often have inferior clinical outcomes ([@pkz039-B2]). These outcomes have more recently come under scrutiny as reimbursement strategies designed to incentivize performance have gained traction and have been criticized for unfairly penalizing safety-net providers who are already under financial duress ([@pkz039-B5],[@pkz039-B6]).

A number of studies have suggested that, even when controlling for a more complex patient population, the quality of surgical care at SNH remains inferior to the care rendered at non-SNH ([@pkz039-B7]). Patients at SNH less frequently undergo minimally invasive surgery, have longer lengths of stay, and higher readmission and postoperative mortality rates ([@pkz039-B8]). Within oncology, the data are mixed. Pancreatic cancer patients at SNH have equivalent surgical resection margins, chemotherapy rates, and 5-year stage-specific survival ([@pkz039-B13]). However, patients with glioblastoma are less likely to receive standard-of-care treatment and have reduced overall survival ([@pkz039-B14]).

For women with gynecologic malignancies, individual characteristics such as race and insurance status have been studied as predictors of outcomes. Yet beyond hospital and surgeon volume, the role of hospital characteristics in defining patient outcomes has been poorly described for this patient population. Specifically, the relationship between safety-net status and gynecologic cancer care remains unexplored. The objective of our study was to examine the quality of care, readmission rates, and survival of women with uterine, ovarian, or cervical cancer treated at SNH compared with those treated at non-SNH.

Methods
=======

Data Source
-----------

We used the National Cancer Database (NCDB) for this analysis. NCDB is a nationwide oncology hospital registry developed and maintained by the American Cancer Society and the American College of Surgeons ([@pkz039-B15]). It captures approximately 70% of all patients with new cancer diagnoses at more than 1500 American hospitals affiliated with the Commission on Cancer (CoC). This study was deemed exempt by the Columbia University Institutional Review Board.

Study Cohort
------------

We identified women diagnosed with an index diagnosis of invasive uterine, ovarian, or cervical cancer from 2004 to 2015. [Figure 1](#pkz039-F1){ref-type="fig"} illustrates cohort selection. We used the unique facility identifiers to select hospitals at which these patients received care. The payer mix of each hospital was analyzed. The calculation of SNH status was based on the proportion of uninsured patients and Medicaid recipients within a specific hospital. The hospitals were stratified into quartiles based on these proportions. Patients with unknown insurance status (2%) were not included in this calculation or the analysis. Each hospital was classified into the following quartiles based on the proportion of patients who were uninsured or Medicaid recipients: lowest Medicaid payer mix, low Medicaid payer mix, high Medicaid payer mix, and highest Medicaid payer mix. Consistent with prior policy reports ([@pkz039-B3]), the hospitals comprising the highest Medicaid payer mix quartile were categorized as SNH ([Figure 2](#pkz039-F2){ref-type="fig"}). After the calculation of SNH, the study cohort was further restricted to include patients with pathologically confirmed invasive gynecologic cancers. Patients with multiple cancer diagnoses were identified by their first case of cancer.

![Cohort selection flowchart.](pkz039f1){#pkz039-F1}

![Hospital quartiles by Medicaid and uninsured payer mix.](pkz039f2){#pkz039-F2}

Patient and Hospital Characteristics
------------------------------------

Patient characteristics included cancer type (uterine, ovarian, cervical), patient's age (\<40, 40--49, 50--59, 60--69, 70--79, and ≥80 years), race or ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, and others), insurance status (private, Medicare, Medicaid, uninsured, and other government), zip code-level median household income (\<\$30 000, \$30 000--\$35 999, \$36 000--\$45 999, and ≥\$46 000), zip-code level education (≥29%, 20%--28.9%, 14%--19.9%, and \<14% of adults without a high school diploma), and patients' residential location (metropolitan, urban, rural, and unknown). Comorbidities were reported based on the Charlson/Deyo comorbidity score and categorized as 0, 1, or at least 2 conditions ([@pkz039-B16]).

Hospital characteristics included region of the country (East, South, Midwest, West), facility type (community, comprehensive community, academic/research, integrated network), and hospital annualized volume for each cancer site calculated as the total number of patients divided by the number of years in which a given hospital treated at least one patient.

Tumor Characteristics
---------------------

Tumor characteristics included the grade of tumor differentiation (well, moderate, poor, unknown), stage according to American Joint Committee on Cancer criteria and International Federation of Gynecology & Obstetrics system (I, II, III, IV, unknown), and histology based on cancer type. Uterine cancer histologies included endometrioid, serous, clear cell, carcinosarcoma, sarcoma, and other or unknown. Ovarian cancer histologies included serous, mucinous, endometrioid, clear cell, transitional cell, epithelial nonspecific, and other or unknown. Cervical cancer histologies included squamous cell, adenocarcinoma, adenosquamous, and other or unknown.

Quality Metrics and Outcomes
----------------------------

Quality metrics for treatment were derived from evidence-based recommendations ([Table 1](#pkz039-T1){ref-type="table"}). For endometrial cancer, we evaluated the proportion of patients with stage I tumors who underwent minimally invasive hysterectomy ([@pkz039-B17]), lymph node assessment for women with stage IB grade 2 or 3, or stage II endometrioid adenocarcinomas ([@pkz039-B20],[@pkz039-B21]), and the use of chemotherapy for stage III--IVB disease ([@pkz039-B22],[@pkz039-B23]). For ovarian cancer patients, we assessed performance of debulking (cytoreduction and/or omentectomy) for patients with stage IIA--IV tumors ([@pkz039-B24]), proportion of lymph node dissection in cancer-directed surgery for patients with stage I--IIIB tumors ([@pkz039-B29]), use of chemotherapy for patients with high-risk early-stage tumors (stage IA/B grade 3, stage IC any grade, or stage IA/B/C clear cell) ([@pkz039-B32]), and use of chemotherapy for patients with stage III--IV tumors who underwent primary cytoreduction ([@pkz039-B35]). For patients with cervical cancer, we assessed performance of a radical hysterectomy (vs simple hysterectomy) for stage IA2, IB1, IIA1, and IIA2 patients who had hysterectomy ([@pkz039-B36]); performance of pelvic lymph node dissection in patients with stage IA2, IB1, IIA1, and IIA2 tumors who underwent surgery ([@pkz039-B37]); and use of concurrent chemotherapy in patients with stages IB2, IIA2, IIB, IIIA, IIIB, and IVA undergoing radiation treatment ([@pkz039-B38]).

###### 

Quality indicators for the study cohort

  Quality indicators                                                              Detailed descriptions                                                                                         Total patients for calculation[\*](#tblfn1){ref-type="table-fn"}
  ------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------
  Uterine cancer                                                                                                                                                                                
   Minimally invasive surgery ([@pkz039-B17])                                     Minimally invasive hysterectomy; stage I disease                                                              126 037
   Lymph node assessment ([@pkz039-B20],[@pkz039-B21])                            Lymph node assessment in cancer surgery; endometroid adenocarcinoma stage IB grade 2 or 3, stage II           28 738
   Chemotherapy for advanced stage ([@pkz039-B22],[@pkz039-B23])                  Chemotherapy; stage III--IVB                                                                                  40 865
   30-day readmission                                                             Readmission within 30 days of cancer-directed surgery                                                         317 066
   30-day mortality                                                               Perioperative mortality within 30 days of cancer-directed surgery                                             286 688
  Ovarian cancer                                                                                                                                                                                
   Debulking ([@pkz039-B24])                                                      Cytoreduction and/or omentectomy; stage IIA--IV                                                               60 114
   Lymph node assessment ([@pkz039-B29])                                          Lymph node assessment in cancer surgery; stage I--IIIB                                                        43 984
   Chemotherapy for high-risk early-stage disease ([@pkz039-B32],[@pkz039-B33])   Chemotherapy; stage IA/B grade 3, stage IC any grade, stage IA/B/C with clear cell histology                  14 331
   Chemotherapy for advanced stage ([@pkz039-B35])                                Chemotherapy; stage IIB, IIC, III, IV patients who underwent primary cytoreduction                            79 450
   30-day readmission                                                             Readmission within 30 days of cancer-directed surgery                                                         116 358
   30-day mortality                                                               Perioperative mortality within 30 days of cancer-directed surgery                                             108 571
  Cervical cancer                                                                                                                                                                               
   Radical hysterectomy ([@pkz039-B37])                                           Radical hysterectomy; stage IA2, IB1, IIA1, IIA2                                                              12 774
   Lymph node assessment ([@pkz039-B37])                                          Pelvic lymph node dissection with radical hysterectomy; stage IA2, IB1, IIA1, IIA2                            7108
   Concurrent chemoradiation ([@pkz039-B38])                                      Concurrent chemotherapy (6--8 weeks); stage IB2, IIA2, IIB, IIIA, IIIB, IVA patients who received radiation   30 777
   30-day readmission                                                             Readmission within 30 days of cancer-directed surgery                                                         53 015
   30-day mortality                                                               Perioperative mortality within 30 days of cancer-directed surgery                                             48 384

To reduce heterogeneity within the quality analysis, patients with uterine cancer who did not undergo hysterectomy were excluded. All patients with cervical or ovarian cancer were included regardless of nonsurgical treatment. Quality indicators were assessed for the following years: 2010--2015 for minimally invasive surgery among uterine cancer patients, 2006--2015 for chemotherapy in advanced-stage uterine cancer patients, 2004--2015 for the remainder of the quality markers.

For patients who underwent surgery, we assessed all-cause mortality and readmission within 30 days of the procedure. Five-year survival was measured from the date of diagnosis until last follow-up or death from any cause.

Statistical Analysis
--------------------

Following hospital stratification, all analyses were conducted at the patient level. Differences in the distribution of categorical variables were assessed using chi-squared tests. The unadjusted rates of adherence to each quality metric were compared across the hospital quartiles by cancer site. Multivariable Poisson regression models based on the generalized estimating equations, to account for patients clustered within hospitals, were developed to estimate the association between treatment at SNH and adherence to each quality metric compared with the lowest quartile hospitals for each cancer site. This model was adjusted for patient demographics, tumor characteristics, and hospital factors. The results are reported as adjusted risk ratio with 95% confidence intervals (CI).

Survival analysis was restricted to patients diagnosed from 2004 to 2014 who had complete vital status data. Kaplan-Meier curves were used to calculate observed 5-year survival. Marginal multivariable Cox proportional-hazard models were developed to determine all-cause mortality differences between patients receiving services at SNH vs those at the lowest quartile hospitals after accounting for hospital clustering and observed confounders. To determine if treatment differences between hospitals may influence survival, we developed two models. In the first model, we adjusted for patient, tumor, and hospital characteristics. In the second model, we adjusted for cancer site-specific treatment (guideline-appropriate surgery, chemotherapy, and radiation therapy) in addition to those variables in the first model. Results are reported as adjusted hazard ratios (aHR) with 95% confidence interval. The assumption of proportionality was assessed by using Martingale residuals for each variable in the model.

Sensitivity Analysis
--------------------

We undertook a series of sensitivity analyses to examine the robustness of the findings. In the first sensitivity analysis, we limited the cohort to only women who received all their care at the same hospital (ie, no hospital transfers). In the second, we defined SNH using the CMS cutoff of 30% for the volume of inpatient uninsured or Medicaid recipients.

All analyses were performed with SAS 9.4 (SAS Institute Inc, Cary, NC), and R 3.5.1 (Foundation for Statistical Computing, Vienna, Austria) with "ggplot2" package. All statistical tests were two-sided. A *P* value of less than .05 was considered statistically significant.

Results
=======

Hospital, Patient, and Tumor Characteristics
--------------------------------------------

We identified a total of 594 750 patients treated at 1340 hospitals ([Table 2](#pkz039-T2){ref-type="table"}). Facilities classified as SNH had an average of 20.7% (range=15.8%--93.1%) uninsured or Medicaid patients ([Figure 2](#pkz039-F2){ref-type="fig"}). In contrast, hospitals in the lowest quartile had an average of 4.4% (range 0%--6.6%) of uninsured or Medicaid patients.

###### 

Patient and hospital factors stratified by percentage of Medicaid/uninsured patients at a given hospital

                                                                     Lowest Medicaid payer mix   Low Medicaid payer mix   High Medicaid payer mix   Highest Medicaid payer mix   *P*
  ------------------------------------------------------------------ --------------------------- ------------------------ ------------------------- ---------------------------- ---------
  Median proportion of Medicaid and uninsured patients               4.4%                        8.6%                     12.8%                     20.7%                        
  Patients                                                           144 136 (24.2)              156 736 (26.4)           153 141 (25.8)            140 737 (23.7)               
  Hospitals                                                          335 (25.0)                  334 (24.9)               336 (25.1)                335 (25)                     
  Cancer type                                                                                                                                                                    \<.0001
   Uterine                                                           91 840 (63.7)               97 179 (62.0)            93 039 (60.8)             75 801 (53.9)                
   Ovarian                                                           34 741 (24.1)               36 689 (23.4)            34 933 (22.8)             30 610 (21.7)                
   Cervical                                                          17 555 (12.2)               22 868 (14.6)            25 169 (16.4)             34 326 (24.4)                
  Age, y                                                                                                                                                                         \<.0001
   \<40                                                              9622 (6.7)                  12 073 (7.7)             12 675 (8.3)              15 715 (11.2)                
   40--49                                                            17 577 (12.2)               20 077 (12.8)            20 185 (13.2)             22 552 (16.0)                
   50--59                                                            38 691 (26.8)               41 261 (26.3)            40 455 (26.4)             37 675 (26.8)                
   60--69                                                            42 146 (29.2)               44 879 (28.6)            43 357 (28.3)             36 829 (26.2)                
   70--79                                                            24 233 (16.8)               26 160 (16.7)            24 727 (16.1)             19 542 (13.9)                
   ≥80                                                               11 867 (8.2)                12 286 (7.8)             11 742 (7.7)              8424 (6.0)                   
  Race                                                                                                                                                                           \<.0001
   Non-Hispanic: white                                               111 974 (77.7)              118 982 (75.9)           114 623 (74.8)            85 776 (60.9)                
   Non-Hispanic: black                                               9750 (6.8)                  15 229 (9.7)             13 364 (8.7)              22 694 (16.1)                
   Hispanic                                                          5237 (3.6)                  9100 (5.8)               8737 (5.7)                19 162 (13.6)                
   Other                                                             5991 (4.2)                  5041 (3.2)               5615 (3.7)                6889 (4.9)                   
   Unknown                                                           11 184 (7.8)                8384 (5.3)               10 802 (7.1)              6216 (4.4)                   
  Insurance status                                                                                                                                                               \<.0001
   Private                                                           85 224 (59.1)               84 019 (53.6)            75 790 (49.5)             54 555 (38.8)                
   Medicare                                                          51 379 (35.6)               57 268 (36.5)            54 946 (35.9)             44 393 (31.5)                
   Medicaid                                                          4417 (3.1)                  9287 (5.9)               13 612 (8.9)              23 617 (16.8)                
   Uninsured                                                         2273 (1.6)                  4743 (3.0)               7013 (4.6)                16 080 (11.4)                
   Other government                                                  843 (0.6)                   1419 (0.9)               1780 (1.2)                2092 (1.5)                   
  Median household income[\*](#tblfn2){ref-type="table-fn"}                                                                                                                      \<.0001
   \<\$30 000                                                        9058 (6.3)                  16 640 (10.6)            18 576 (12.1)             33 914 (24.1)                
   \$30 000--\$35 999                                                14 678 (10.2)               26 151 (16.7)            30 387 (19.8)             31 409 (22.3)                
   \$36 000--\$45 999                                                31 870 (22.1)               43 398 (27.7)            47 949 (31.3)             36 722 (26.1)                
   \$46 000+                                                         83 270 (57.8)               65 325 (41.7)            51 477 (33.6)             33 437 (23.8)                
   Not available                                                     5260 (3.6)                  5222 (3.3)               4752 (3.1)                5255 (3.7)                   
  Less than high school education[†](#tblfn3){ref-type="table-fn"}                                                                                                               \<.0001
   ≥ 29%                                                             14 015 (9.7)                20 653 (13.2)            22 353 (14.6)             44 500 (31.6)                
   20--28.9%                                                         23 928 (16.6)               33 619 (21.4)            38 200 (24.9)             38 517 (27.4)                
   14--19.9%                                                         31 250 (21.7)               39 839 (25.4)            39 622 (25.9)             24 933 (17.7)                
   \<14%                                                             69 674 (48.3)               57 389 (36.6)            48 181 (31.5)             27 515 (19.6)                
   Not available                                                     5269 (3.7)                  5236 (3.3)               4785 (3.1)                5272 (3.7)                   
  Urban/rural                                                                                                                                                                    \<.0001
   Metropolitan                                                      124 874 (86.6)              126 930 (81.0)           114 296 (74.6)            107 915 (76.7)               
   Urban                                                             12 517 (8.7)                22 772 (14.5)            29 583 (19.3)             25 783 (18.3)                
   Rural                                                             1907 (1.3)                  2696 (1.7)               3529 (2.3)                3153 (2.2)                   
   Unknown                                                           4838 (3.4)                  4338 (2.8)               5733 (3.7)                3886 (2.8)                   
  Comorbidity score                                                                                                                                                              \<.0001
   0                                                                 113 778 (78.9)              121 201 (77.3)           118 211 (77.2)            110 211 (78.3)               
   1                                                                 24 441 (17.0)               28 406 (18.1)            27 902 (18.2)             23 944 (17.0)                
   \>2                                                               5917 (4.1)                  7129 (4.5)               7028 (4.6)                6582 (4.7)                   
  Year of diagnosis                                                                                                                                                              \<.0001
   2004                                                              9128 (6.3)                  10 202 (6.5)             10 277 (6.7)              9548 (6.8)                   
   2005                                                              9729 (6.7)                  10 930 (7.0)             10 577 (6.9)              10 285 (7.3)                 
   2006                                                              10 272 (7.1)                11 626 (7.4)             11 135 (7.3)              10 483 (7.4)                 
   2007                                                              10 939 (7.6)                12 040 (7.7)             11 739 (7.7)              10 960 (7.8)                 
   2008                                                              11 389 (7.9)                12 507 (8.0)             12 290 (8.0)              11 552 (8.2)                 
   2009                                                              11 714 (8.1)                13 408 (8.6)             12 617 (8.2)              11 702 (8.3)                 
   2010                                                              12 103 (8.4)                13 449 (8.6)             12 738 (8.3)              11 624 (8.3)                 
   2011                                                              12 659 (8.8)                13 915 (8.9)             13 203 (8.6)              12 131 (8.6)                 
   2012                                                              13 086 (9.1)                14 023 (8.9)             14 009 (9.1)              12 442 (8.8)                 
   2013                                                              13 855 (9.6)                14 265 (9.1)             14 379 (9.4)              13 096 (9.3)                 
   2014                                                              14 489 (10.1)               14 945 (9.5)             15 060 (9.8)              13 380 (9.5)                 
   2015                                                              14 773 (10.2)               15 426 (9.8)             15 117 (9.9)              13 534 (9.6)                 
  Facility location                                                                                                                                                              \<.0001
   Eastern                                                           42 068 (29.2)               32 262 (20.6)            29 849 (19.5)             16 888 (12.0)                
   South                                                             21 198 (14.7)               41 533 (26.5)            39 335 (25.7)             48 087 (34.2)                
   Midwest                                                           50 569 (35.1)               55 503 (35.4)            43 649 (28.5)             34 114 (24.2)                
   West                                                              20 679 (14.3)               15 365 (9.8)             27 633 (18.0)             25 933 (18.4)                
   Unknown                                                           9622 (6.7)                  12 073 (7.7)             12 675 (8.3)              15 715 (11.2)                
  Facility type                                                                                                                                                                  \<.0001
   Community cancer program                                          5412 (3.8)                  7903 (5.0)               8223 (5.4)                10 633 (7.6)                 
   Comprehensive community cancer program                            74 093 (51.4)               72 032 (46.0)            50 482 (33.0)             24 539 (17.4)                
   Academic/research program                                         44 930 (31.2)               39 702 (25.3)            66 324 (43.3)             77 529 (55.1)                
   Integrated network cancer program                                 10 079 (7.0)                25 026 (16.0)            15 437 (10.1)             12 321 (8.8)                 
   Unknown                                                           9622 (6.7)                  12 073 (7.7)             12 675 (8.3)              15 715 (11.2)                

Zip code median household income.

Zip code average.

SNH had a higher relative percentage of patients with cervical cancer and a lower number of uterine cancer patients than other centers (*P* \< .0001). Patients at SNH were younger (11.4% vs 6.7% were age \<40 years), more frequently black (16.1% vs 6.8%) or Hispanic (13.6% vs 3.6%), and lived in metropolitan zip codes with lower income and lower educational attainment (*P *\<* *.0001 for all). SNH were more commonly academic medical centers and more frequently located in the South (*P *\<* *.0001 for both).

Among all three cancer types, women at SNH more commonly presented with advanced-stage disease (*P *\<* *.0001 for all) ([Table 3](#pkz039-T3){ref-type="table"}). Patients with uterine cancer at SNH more commonly had nonendometrioid histologic variants and more commonly had high-grade tumors (*P *\<* *.001 for both). Patients with cervical cancer managed at SNH were more likely to have squamous cell tumors and moderate or poorly differentiated neoplasms (*P *\<* *.0001 for both).

###### 

Oncologic characteristics of the study cohort stratified by tumor type and hospital-level percentage of uninsured or Medicaid patients

                                  Lowest Medicaid payer mix   Low Medicaid payer mix   High Medicaid payer mix   Highest Medicaid payer mix   
  ------------------------------- --------------------------- ------------------------ ------------------------- ---------------------------- ---------
  Uterine cancer (n = 357 859)                                                                                                                
  Stage                                                                                                                                       \<.0001
   I                              58 360 (63.5)               60 100 (61.8)            57 883 (62.2)             43 701 (57.7)                 
   II                             4732 (5.2)                  5559 (5.7)               5448 (5.9)                5120 (6.8)                    
   III                            8193 (8.9)                  9064 (9.3)               9205 (9.9)                8094 (10.7)                   
   IV                             4426 (4.8)                  4651 (4.8)               4789 (5.1)                4748 (6.3)                    
   Unknown                        16 129 (17.6)               17 805 (18.3)            15 714 (16.9)             14 138 (18.7)                
  Histology                                                                                                                                   \<.0001
   Endometrioid                   63 151 (68.8)               64 819 (66.7)            63 033 (67.7)             47 474 (62.6)                
   Serous                         5356 (5.8)                  5712 (5.9)               5617 (6.0)                5179 (6.8)                    
   Clear cell                     1143 (1.2)                  1325 (1.4)               1207 (1.3)                1099 (1.4)                    
   Carcinosarcoma                 4104 (4.5)                  4615 (4.7)               4429 (4.8)                4377 (5.8)                    
   Sarcoma                        3629 (4.0)                  3982 (4.1)               3617 (3.9)                3682 (4.9)                    
   Other/unknown                  14 457 (15.7)               16 726 (17.2)            15 136 (16.3)             13 990 (18.5)                 
  Grade                                                                                                                                       \<.0001
   Well                           35 168 (38.3)               35 464 (36.5)            34 090 (36.6)             24 873 (32.8)                 
   Moderate                       21 635 (23.6)               23 249 (23.9)            21 846 (23.5)             18 112 (23.9)                 
   Poorly                         19 884 (21.7)               21 667 (22.3)            21 234 (22.8)             18 561 (24.5)                 
   Unknown                        15 153 (16.5)               16 799 (17.3)            15 869 (17.1)             14 255 (18.8)                 
  Ovarian cancer (n = 136 973)                                                                                                                
  Stage                                                                                                                                       \<.0001
   I                              7596 (21.9)                 7651 (20.9)              7222 (20.7)               6281 (20.5)                   
   II                             2856 (8.2)                  2860 (7.8)               2685 (7.7)                2321 (7.6)                    
   III                            12 678 (36.5)               13 187 (35.9)            13 221 (37.8)             11 356 (37.1)                 
   IV                             5310 (15.3)                 5579 (15.2)              5446 (15.6)               4859 (15.9)                   
   Unknown                        6301 (18.1)                 7412 (20.2)              6359 (18.2)               5793 (18.9)                   
  Histology                                                                                                                                   \<.0001
   Serous                         17 784 (51.2)               18 331 (50.0)            17 823 (51.0)             15 240 (49.8)                
   Mucinous                       1903 (5.5)                  2013 (5.5)               2098 (6.0)                2003 (6.5)                    
   Endometrioid                   3329 (9.6)                  3250 (8.9)               2838 (8.1)                2437 (8.0)                    
   Clear cell                     2282 (6.6)                  2198 (6.0)               2021 (5.8)                1611 (5.3)                    
   Transitional cell              114 (0.3)                   113 (0.3)                113 (0.3)                 114 (0.4)                     
   Epithelial tumor nonspecific   5042 (14.5)                 5836 (15.9)              5344 (15.3)               4813 (15.7)                   
   Other/unknown                  4287 (12.3)                 4948 (13.5)              4696 (13.4)               4392 (14.3)                   
  Grade                                                                                                                                       \<.0001
   Well                           2685 (7.7)                  2974 (8.1)               2618 (7.5)                2317 (7.6)                    
   Moderate                       4118 (11.9)                 4611 (12.6)              4459 (12.8)               4011 (13.1)                   
   Poorly                         18 897 (54.4)               19 290 (52.6)            18 598 (53.2)             15 042 (49.1)                 
   Unknown                        9041 (26.0)                 9814 (26.7)              9258 (26.5)               9240 (30.2)                   
  Cervical cancer (n = 99 918)                                                                                                                
  Stage                                                                                                                                       \<.0001
   I                              8970 (51.1)                 11 199 (49.0)            11 757 (46.7)             14 598 (42.5)                 
   II                             2180 (12.4)                 3145 (13.8)              3606 (14.3)               5765 (16.8)                   
   III                            2772 (15.8)                 3867 (16.9)              4893 (19.4)               7320 (21.3)                   
   IV                             2002 (11.4)                 2566 (11.2)              3070 (12.2)               4447 (13.0)                   
   Unknown                        1631 (9.3)                  2091 (9.1)               1843 (7.3)                2196 (6.4)                    
  Histology                                                                                                                                   \<.0001
   Squamous cell                  10 823 (61.7)               14 738 (64.4)            16 669 (66.2)             24 547 (71.5)                 
   Adenocarcinoma                 4097 (23.3)                 4758 (20.8)              4981 (19.8)               5233 (15.2)                   
   Adenosquamous                  584 (3.3)                   845 (3.7)                843 (3.3)                 1128 (3.3)                    
   Other/unknown                  2051 (11.7)                 2527 (11.1)              2676 (10.6)               3418 (10.0)                   
  Grade                                                                                                                                       \<.0001
   Well                           2067 (11.8)                 2573 (11.3)              2651 (10.5)               2945 (8.6)                    
   Moderate                       5350 (30.5)                 7096 (31.0)              7883 (31.3)               11 304 (32.9)                 
   Poorly                         5561 (31.7)                 6828 (29.9)              7872 (31.3)               10 554 (30.7)                 
   Unknown                        4577 (26.1)                 6371 (27.9)              6763 (26.9)               9523 (27.7)                   

Quality of Care
---------------

Patients with uterine cancer treated at SNH were less likely to undergo minimally invasive surgery (62.3% vs 75.9%, *P *\<* *.0001) and nodal assessment (77.8% vs 83.1%, *P *\<* *.05) but more likely to receive chemotherapy (74.5% vs 73.3%, *P *\<* *.05) for advanced-stage disease ([Table 4](#pkz039-T4){ref-type="table"}). Patients with ovarian cancer who received care at SNH were less likely to undergo debulking surgery (83.6% vs 86.9%) or nodal assessment (65.3% vs 74.1%), but early and advanced-stage patients were more likely to receive chemotherapy at SNH than at the lowest quartile hospitals (72.0% vs 68.6% and 84.0% vs 81.8%, respectively) (*P *\<* *.05 for all). Cervical cancer patients who received care at SNH were less likely to undergo radical hysterectomy (56.6% vs 56.1%) and pelvic lymph node dissection (96.5% vs 97.7%) and were less likely to receive concurrent chemoradiotherapy (59.6% vs 65.3%) (*P *\<* *.05 for all). For all three cancer sites, there were no differences in 30-day readmission or perioperative mortality rates following surgery.

###### 

Quality metric adherence stratified by tumor type and hospital quartiles of Medicaid/uninsured patients[\*](#tblfn4){ref-type="table-fn"}

                                         Crude quality metrics rate, No. (%)   aRR (95% CI) SNH vs lowest                                   
  -------------------------------------- ------------------------------------- ---------------------------- --------------- --------------- ------------------------------------------------------
  Uterine cancer                                                                                                                            
   Minimally invasive surgery            26 051 (75.9)                         26 023 (75.5)                24 693 (74.4)   14 979 (62.3)   0.85 (0.79 to 0.91)[‡](#tblfn5){ref-type="table-fn"}
   Lymph node assessment                 6098 (83.1)                           6241 (81.4)                  6196 (81.5)     4768 (77.8)     0.96 (0.92 to 0.99)[†](#tblfn5){ref-type="table-fn"}
   Chemotherapy, advanced stage          7173 (73.3)                           7688 (72.2)                  8035 (74.4)     7166 (74.5)     1.06 (1.02 to 1.10)[†](#tblfn5){ref-type="table-fn"}
   30-day readmission                    3499 (4.2)                            3706 (4.3)                   3667 (4.4)      3485 (5.4)      1.15 (0.89 to 1.49)
   30-day mortality                      454 (0.6)                             562 (0.7)                    530 (0.7)       470 (0.8)       1.01 (0.85 to 1.19)
  Ovarian cancer                                                                                                                            
   Debulking                             13 140 (86.9)                         13 518 (86.3)                13 318 (84.6)   11 370 (83.6)   0.98 (0.95 to 1.00)[†](#tblfn5){ref-type="table-fn"}
   Lymph node assessment                 8537 (74.1)                           8454 (72.6)                  7890 (71.3)     6368 (65.3)     0.90 (0.86 to 0.96)[†](#tblfn5){ref-type="table-fn"}
   Chemotherapy, high-risk early stage   2596 (68.6)                           2689 (69.8)                  2654 (72.2)     2168 (72.0)     1.08 (1.02 to 1.15)[†](#tblfn5){ref-type="table-fn"}
   Chemotherapy, advanced stage          11 291 (81.8)                         11 932 (81.7)                12 357 (83.9)   10 663 (84.0)   1.06 (1.03 to 1.10)[†](#tblfn5){ref-type="table-fn"}
   30-day readmission                    2382 (8.0)                            2498 (8.0)                   2560 (8.6)      2077 (8.1)      1.01 (0.81 to 1.26)
   30-day mortality                      497 (1.8)                             603 (2.1)                    563 (2.0)       486 (2.0)       1.10 (0.93 to 1.31)
  Cervical cancer                                                                                                                           
   Radical hysterectomy                  1421 (56.1)                           1834 (55.9)                  1787 (54.2)     2074 (56.6)     0.97 (0.90 to 1.05)
   Lymph node assessment                 1743 (97.7)                           1798 (98)                    1743 (97.7)     1998 (96.5)     0.98 (0.97 to 0.99)[†](#tblfn5){ref-type="table-fn"}
   Concurrent chemoradiation             2896 (65.3)                           4149 (64.5)                  5129 (64.6)     7135 (59.6)     0.95 (0.90 to 0.99)[†](#tblfn5){ref-type="table-fn"}
   30-day readmission                    474 (4.5)                             656 (4.9)                    698 (5.2)       882 (5.6)       1.11 (0.84 to 1.47)
   30-day mortality                      27 (0.3)                              38 (0.3)                     39 (0.3)        46 (0.3)        1.19 (0.68 to 2.10)

Multivariable Poisson regression model adjusted for age, race, insurance status, zip code median household income and education level, urban/rural, comorbidity score, year of diagnosis, cancer histology/grade/stage, hospital factors (hospital annualized volume, hospital region, hospital type), and hospital clustering. aRR = adjusted risk ratio; CI = confidence interval; SNH = safety-net hospital.

*P* \< .05. ‡*P* \< .0001.

Survival Analysis
-----------------

Crude 5-year survival is presented in [Table 5](#pkz039-T5){ref-type="table"}. For women with uterine cancer, there was no difference in overall mortality. For women with ovarian cancer, although there was no difference in overall mortality for those with stage I--III disease, there was a survival disparity between SNH and non-SNH for women with stage IV ovarian cancer (5-year survival, 22.0% vs 24.5%; aHR for overall mortality = 1.10, 95% CI = 1.03 to 1.17). For women with cervical cancer, there were no survival differences for stage I and stage IV disease, yet there were modest decreases in overall mortality both for stage II (63.2% vs 65.9%, aHR = 1.13, 95% CI = 1.02 to 1.26) and stage III (45.2% vs 47.8%, aHR = 1.10, 95% CI = 1.01 to 1.19).

###### 

Survival stratified by tumor type and hospital quartiles of Medicaid and uninsured patients[\*](#tblfn6){ref-type="table-fn"}

                    Crude 5-year survival rate (95% CI)   aHR (95% CI) for overall mortality Highest vs lowest Medicaid payer mix                                                                                                      
  ----------------- ------------------------------------- ------------------------------------------------------------------------- --------------------- --------------------- ------------------------------------------------------ ------------------------------------------------------
  Uterine cancer                                                                                                                                                                                                                       
   Stage I          90.6 (90.3 to 90.9)                   89.8 (89.5 to 90.1)                                                       89.6 (89.3 to 89.9)   88.9 (88.6 to 89.3)   1.07 (1.00 to 1.15)                                    1.07 (0.99 to 1.14)
   Stage II         76.8 (75.3 to 78.3)                   76.0 (74.6 to 77.3)                                                       75.2 (73.8 to 76.5)   74.0 (72.6 to 75.5)   1.10 (1.00 to 1.22)                                    1.10 (0.99 to 1.22)
   Stage III        57.7 (56.3 to 59.2)                   56.6 (55.3 to 57.8)                                                       56.1 (54.9 to 57.4)   54.5 (53.2 to 55.9)   1.03 (0.95 to 1.10)                                    1.04 (0.97 to 1.12)
   Stage IV         23.4 (21.6 to 25.3)                   23.1 (21.5 to 24.8)                                                       22.8 (21.2 to 24.4)   24.1 (22.5 to 25.8)   1.00 (0.93 to 1.08)                                    1.01 (0.94 to 1.10)
  Ovarian cancer                                                                                                                                                                                                                       
   Stage I          87.7 (86.8 to 88.6)                   87.4 (86.4 to 88.2)                                                       87.2 (86.3 to 88.1)   87.0 (85.9 to 88.0)   0.97 (0.86 to 1.09)                                    0.96 (0.85 to 1.07)
   Stage II         71.0 (69.0 to 73.0)                   71.4 (69.4 to 73.3)                                                       70.7 (68.6 to 72.7)   69.2 (67.0 to 71.4)   1.05 (0.92 to 1.21)                                    1.04 (0.92 to 1.19)
   Stage III        40.6 (39.6 to 41.6)                   39.6 (38.6 to 40.6)                                                       39.2 (38.2 to 40.2)   40.2 (39.2 to 41.3)   1.01 (0.95 to 1.07)                                    1.01 (0.95 to 1.07)
   Stage IV         24.5 (23.1 to 25.9)                   23.4 (22.1 to 24.8)                                                       23.2 (21.9 to 24.6)   22.0 (20.6 to 23.4)   1.10 (1.03 to 1.17)[†](#tblfn7){ref-type="table-fn"}   1.11 (1.03 to 1.19)[†](#tblfn7){ref-type="table-fn"}
  Cervical cancer                                                                                                                                                                                                                      
   Stage I          88.6 (87.8 to 89.4)                   88.2 (87.5 to 88.9)                                                       87.0 (86.2 to 87.7)   85.3 (84.7 to 86.0)   1.09 (0.98 to 1.21)                                    1.03 (0.92 to 1.15)
   Stage II         65.9 (63.5 to 68.2)                   64.4 (62.5 to 66.4)                                                       62.3 (60.5 to 64.1)   63.2 (61.8 to 64.7)   1.16 (1.04 to 1.28)[†](#tblfn7){ref-type="table-fn"}   1.13 (1.02 to 1.26)[†](#tblfn7){ref-type="table-fn"}
   Stage III        47.8 (45.6 to 50.0)                   47.3 (45.4 to 49.1)                                                       45.9 (44.2 to 47.5)   45.2 (43.9 to 46.6)   1.10 (1.02 to 1.20)[†](#tblfn7){ref-type="table-fn"}   1.10 (1.01 to 1.19)[†](#tblfn7){ref-type="table-fn"}
   Stage IV         15.5 (13.6 to 17.4)                   14.9 (13.3 to 16.6)                                                       14.2 (12.7 to 15.8)   17.2 (15.9 to 18.6)   1.02 (0.93 to 1.11)                                    1.01 (0.92 to 1.11)

Multivariable Cox proportional-hazard model 1 adjusted for patient factors (age, race, insurance status, zip code median household income and education level, urban/rural, comorbidity score, year of diagnosis, cancer stage/grade/histology), hospital factors (hospital annualized volume, hospital region, hospital type, hospital clustering). Model 2 adjusted for covariates in model 1 plus treatment variables (guideline-appropriate surgery, chemotherapy, radiotherapy). aHR = adjusted hazard ratio; CI = confidence interval.

*P* \< .05.

Sensitivity Analysis
--------------------

We ran two sensitivity analyses to validate our results. These data are demonstrated in [Supplementary Table 1](#sup1){ref-type="supplementary-material"} (available online). For the first sensitivity analysis, we limited the cohort to women who received their full course of care at a single hospital. None of the quality metrics or survival outcomes were changed from our original analysis. For our second sensitivity analysis, we limited the cohort of patients to those who received care at hospitals serving at least 30% uninsured or Medicaid patients (4.3% of hospitals). Notably, these hospitals had similar surgical volumes as those in the original SNH cohort. We found that differences in surgical quality indicators were more robust but that chemotherapy rates became equivalent. The survival disparities also resolved; the only survival disparity that persisted was in patients with stage III cervical cancer (aHR for overall mortality = 1.13, 95% CI = 1.02 to 1.25).

Discussion
==========

These data demonstrate that women with gynecologic cancers treated at SNH receive a mix of guideline-adherent care and nonguideline-adherent care. Although they more commonly receive lower-quality surgical care than women treated at non-SNH, the rates of adjuvant chemotherapy are equivalent and sometimes higher at SNH. Readmission and 30-day mortality rates are equivalent, yet there is a modest decrease in overall mortality for patients with stage IV ovarian cancer and stage II--III cervical cancer seen at SNH. Importantly, although these differences are statistically significant given our large sample size, they may be less clinically significant and may in fact represent roughly comparable risk-adjusted outcomes between SNH and non-SNH.

The disparities in surgical care between SNH and non-SNH that we identified are consistent with studies from other tumor sites that have noted similar trends. Patients with early-stage non--small cell lung cancer are less likely to undergo curative intent surgery at SNH and patients with glioblastoma managed at SNH are less likely to receive trimodal therapy, undergo gross total resection, receive radiation, and chemotherapy ([@pkz039-B14]). However, in contrast, hospital safety-net status does not affect the rates of complete resection, radiation therapy, and chemotherapy for patients with pancreatic cancer or rectal cancer ([@pkz039-B13],[@pkz039-B41]). Factors that influence quality of care at SNH may vary by procedure type and require further investigation. Interestingly, for gynecological cancers, we found that although the quality of surgical care at SNH was lower than at non-SNH, receipt of evidence-based chemotherapy was higher at SNH for uterine and ovarian cancer patients. Plausibly, based on our lymph node assessment data, these patients are more often incompletely staged, in which setting these patients generally would receive adjuvant chemotherapy.

The association between treatment at an SNH and survival were modest. The most pronounced survival difference we found was for women with stage II--III cervical cancer: those who require complex multimodal therapy with chemotherapy, external beam radiation, and brachytherapy. Adjusting for treatment in our model did not statistically significantly affect overall mortality rates. This is consistent with other work that demonstrates persistent survival differences between SNH and non-SNH despite adjusting for treatment ([@pkz039-B42]). What may affect survival more than the exact treatment regimen are the uncaptured challenges in coordination of care, such as treatment delays, loss to follow-up, lower access to primary care, and preventive health services that are experienced at a disproportionately higher rate for patients who receive care at SNH compared with non-SNH ([@pkz039-B43],[@pkz039-B44]).

We found no association between site of care and immediate perioperative outcomes such as readmission and 30-day mortality. Given the complex social situation of many underinsured patients who are treated at SNH, these findings underscore the importance of comprehensive risk adjustment in calculating these publicly available and frequently cited quality metrics ([@pkz039-B45]). Controlling both for patient and hospital factors generally seems to eliminate the differences in crude rates of 30-day readmission and mortality. For patients undergoing major cancer surgery, risk-adjusted readmission rates have been demonstrated to be higher for patients at SNH, yet these differences are eliminated after adjusting for hospital factors, such as the number of beds, ownership, teaching status, and CoC-approved program designation ([@pkz039-B10]).

We recognize several important limitations. First, defining safety-net status remains challenging ([@pkz039-B46]). Our definition of SNH relied on previously described classification criteria ([@pkz039-B8],[@pkz039-B11],[@pkz039-B41],[@pkz039-B47]). However, the hospitals classified as SNH are highly heterogeneous and include a mix of academic medical centers, low-volume community hospitals, and urban teaching facilities. Interestingly, when we limited our safety-net cohort to the top approximately 5% of hospitals that cared for the greatest proportion of uninsured or Medicaid gynecologic cancer patients (≥30%, based on CMS cutoff), the disparities in surgical quality indicators became more pronounced, whereas the disparities in 5-year survival nearly all resolved. Disentangling predictors of quality among SNH and their relationship with outcomes clearly warrants further investigation. Second, although 70% of cancer cases are estimated to be captured within the NCDB, it is limited to CoC-accredited centers, and the hospitals that are not represented in this database may be disproportionately low resourced. These non-CoC centers with 30% of cancer cases may be low volume or have other resource constraints that affect their ability to join the CoC registry and may also affect the quality of care provided to their patients. With this selection bias in mind, we anticipate that the minimal differences we observed in some quality indicators may be an underestimate of the true differences. Third, NCDB does not identify dual-enrolled Medicaid and Medicare patients, so the quartile calculation may be skewed to be more restrictive in its cutoff because the elderly poor would not be included. Lastly, we are unable to account for a number of unmeasured complex social and clinical factors that likely influenced the medical decision making involved in delivering surgical and medical care in our cohort. Drivers of inequity affect patients at multiple levels, from cancer predisposition to systematic barriers in accessing high-quality care, and retrospective study design is limited in assessing variables that cannot be quantified or are not collected.

The quality of surgical oncologic care at SNH faces a number of ongoing challenges. First, many national efforts to promote value-based care provide incentives and disincentives based on adherence to quality metrics and short-term outcomes. Implementation of many of these programs will be challenging for SNH and may financially penalize the most vulnerable hospitals. Second, ongoing trends to concentrate surgical oncological care to high-volume centers may have direct effects on reducing volume at SNH, many of which are not high-volume centers. The possible improvements in outcomes with concentration of care away from SNH must be balanced against the burden these efforts place on vulnerable patient populations that may find it difficult to travel to receive needed care. To avoid widening the racial and socioeconomic disparity gap in patient outcomes, efforts to centralize care must be coupled with evidence-based efforts to make care logistically and financially accessible to all patients.

Overall, this paper contributes to the data demonstrating that surgical care at SNH can be mixed in quality and outcomes. Although more granular data are needed to further investigate these disparities in quality and outcomes, more important work lies in actually eliminating these disparities in care. The American Society of Clinical Oncology established the Health Equity Committee in 2003, the Rural Cancer Care Task Force this year ([@pkz039-B48]), and a series of resource-stratified guidelines ([@pkz039-B49]) with the intention to improve quality of care for targeted populations ([@pkz039-B50]). Kaiser Permanente has piloted the use of social diagnostic codes to identify and address social determinants of health, integrating Electronic Health Record order sets that can trigger referrals for counseling or various social services ([@pkz039-B51]). Recently, the American Medical Association and the UnitedHealth Group have announced a collaboration to create similar billing codes for social determinants of health, which will likely broaden their impact ([@pkz039-B52]).

In sum, these data demonstrate that for women with gynecological malignancies, the quality of surgical care at SNH is lower than at non-SNH facilities; however, other factors that influence cancer outcomes, such as systemic and local treatment, are similar. Despite lower-quality surgical care, survival differences for women treated at SNH and non-SNH are modest. Further research is needed to determine which specific characteristics of SNH affect the provision of quality surgical care for gynecological cancer patients. A concerted effort will be needed to enact the systemic changes necessary to improve quality of care without reducing access for our most vulnerable patients.
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